Commercial-stage company selling EsoGuard, a DNA test for esophageal precancer and cancer, run on samples taken with its EsoCheck cell collection device. Medicare began paying EsoGuard claims in October 2026.
One email, every morning
THE MORNING BRIEF
New clearances, funding rounds and regulatory moves for device founders, and every new how-to guide and template as it lands. No noise, no login.
✓
You're in. The next morning brief lands in your inbox.
No Spam. Unsubscribe anytime.